Related Experiment Videos
Lumbar myelography with iohexol and metrizamide. A comparative multicenter prospective study
Abstract:
Diagnostic quality and adverse reactions associated with metrizamide and iohexol as contrast agents for lumbar myelography were compared in a prospective randomized double-blind study in 350 patients at seven centers. Both contrast media were administered in comparable volumes at a concentration of 180 mg I/ml. Overall quality of radiographic visualization was graded as "good" or "excellent" in 95% of 175 metrizamide studies and in 98% of 175 iohexol myelograms. Ninety-three patients examined with metrizamide (53%) and 130 patients studied with iohexol (74%) experienced no discomfort during or after myelography. The incidence of postmyelographic headache was 38% with metrizamide and 21% with iohexol. Nausea and vomiting were also more common with metrizamide. Five patients examined with metrizamide (3%) experienced transient confusion and disorientation after lumbar myelography. No such reactions were observed after iohexol myelography.
Insights
Iohexol offers superior safety and patient comfort compared to metrizamide for lumbar myelography, with fewer adverse reactions like headache and confusion. Diagnostic quality was excellent for both contrast agents.
Area of Science:
- Radiology
- Neurology
- Medical Imaging
Background:
- Lumbar myelography is a key diagnostic imaging technique.
- Contrast agents are essential for visualizing the spinal canal.
- Metrizamide and iohexol are commonly used iodinated contrast media.
Purpose of the Study:
- To compare the diagnostic quality and adverse reactions of metrizamide and iohexol in lumbar myelography.
- To evaluate patient comfort and safety profiles of the two contrast agents.
Main Methods:
- Prospective, randomized, double-blind study involving 350 patients across seven centers.
- Administration of metrizamide and iohexol at comparable volumes and concentration (180 mg I/ml).
- Assessment of radiographic visualization quality and incidence of adverse events.
Main Results:
- Excellent or good radiographic visualization was achieved in 95% of metrizamide studies and 98% of iohexol studies.
- Iohexol demonstrated a significantly lower incidence of postmyelographic headache (21% vs. 38%) and fewer adverse reactions like nausea, vomiting, and transient confusion.
- A higher percentage of patients experienced no discomfort with iohexol (74%) compared to metrizamide (53%).
Conclusions:
- Iohexol is associated with a more favorable safety profile and improved patient comfort compared to metrizamide for lumbar myelography.
- Both contrast agents provide high-quality diagnostic imaging.
- Iohexol may be preferred due to its reduced adverse event rate.